Startup gets $450K for IV device; Researchers use breath temp to diagnose lung cancer;

@FierceMedDev: ICYMI: Medtronic receives CE mark for upgraded CoreValve TAVR. Report | Follow @FierceMedDev

@VarunSaxena2: UPDATED with CEO comments: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? Report | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. More | Follow @MichaelGFierce

@EmilyWFierce: French devicemaker Carmat outfits second patient with artificial heart, forges ahead with clinical trials. Story | Follow @EmilyWFierce

> Stealth Therapeutics raised $450,000 from investors towards research for its IV device, Invisiport. Story

> Researchers at Italy's University of Foggia discovered that exhaled breath temperature may be a diagnostic tool for lung cancer. More

> Breas Medical acquired the UK's leader in medical ventilators and airway clearance devices, B&D Electromedical. Release

> For the second time, Carmat successfully implanted an artificial heart, which combines synthetic and natural materials derived from a cow heart, into a patient suffering chronic heart failure. Story

Biotech News

@FierceBiotech: You buy a Type 1 diabetes drug in PhIII for $20M in cash and stock and you're "shocked" by trial fraud. Really $HPTX? You didn't suspect? | Follow @FierceBiotech

@JohnCFierce: Running some readership numbers for the year. 70% North America, 18% Europe and 10% Asia, which is a bump for Europe. | Follow @JohnCFierce

@DamianFierce: Hyperion says it was duped into signing a $570M deal for an Israeli biotech. Story | Follow @DamianFierce

@EmilyMFierce: More misplaced pathogens, toxins found in NIH, FDA labs. More from The Washington Post | Follow @EmilyMFierce

> AstraZeneca's self-styled 'blockbuster' benralizumab tanks in severe COPD study. More

> FDA warning dampens Keryx's parade for newly approved kidney drug. Report

> A respiratory expert undermines GSK's case for new asthma drug mepolizumab. Article

Pharma News

@FiercePharma: Top-read special report this weekend: The top 10 pharma companies by 2013 revenue. More | Follow @FiercePharma

@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: New problems at $GSK flu vaccine plant will impact U.S., Canada orders. Article | Follow @CarlyHFierce

> Bristol-Myers socks Merck's brand-new Keytruda with PD-1 patent suit. More

> FDA faces pressure to green-light generic versions of AZ's pricey Nexium. Story

CRO News

> AMRI buys into proteomics to expand its discovery services. Report

> Big Pharma supergroup dishes on de-personalizing clinical data. Story

> CRO Ricerca plans to shed its staff if it can't find a buyer. Article

> Venn lands a $3.1M deal to study a bioresorbable stent. Item

> Catalent eyes another big year after a blockbuster IPO. More

Biotech IT News

> Edico sells its first Dragen bioinformatics processor. More

> George Church talks open data with The Economist. Item

> Propeller Health raises $14.5M to develop its smart inhaler. News

> Apple bars health apps from using iCloud, acting as medical devices. Story

> Big Pharma consortium releases guide to redacting trial data. Article

Animal Health News

> USDA gives conditional approval for Zoetis PEDv vaccine. More

> South Korea lifts ban on zilpaterol feed additives in beef. Report

> Ceva Animal Health expanding into swine market. Story

> Perdue says its chick hatcheries are now antibiotic-free. Article

> Kentucky Horse Racing Commission looking into regulating compounders. Item